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for carriers of the particular AR haplotype, tagged by the 
rs6624304 T-allele.
Results The 15% of men who were carriers of the AR 
haplotype H2 had approximately one-third lower risk for 
PCa diagnosis compared to those with the most common 
H1 variant (OR 0.65; 95% CI 0.45–0.94; p = 0.021). The 
same trend, although not statistically significant (OR 0.75; 
95% CI 0.47–1.24; p = 0.275), was observed in MrOS Swe-
den. When both cohorts were merged, an even more sig-
nificant result was observed (OR 0.68; 95% CI 0.51–0.90; 
p = 0.008).
Conclusions Swedish men with the variant AR haplotype 
H2, tagged by rs6624304, have significantly lower risk of 
PCa compared to those with the more common variant.
Keywords Androgen receptor · Prostate cancer · Genetic 
variants
Introduction
Among European men, prostate cancer (PCa) is the most 
common non-skin cancer, and it is the third most common 
cause of cancer-related mortality [1]. It is well established 
that PCa is hormone-dependent, and androgen deprivation 
therapy with pharmacologic or surgical castration is, there-
fore, a corner stone in the treatment of advanced PCa.
Androgens mediate their effects by altering gene expres-
sion via the androgen receptor (AR), a hormone-induced 
transcription factor. One gene that is dependent on ligand 
activated AR for its expression is Kallikrein-related pepti-
dase 3, encoding for the serine protease known as prostate-
specific antigen (PSA).
The AR gene harbors two tri-nucleotide repeats in the 
coding region; the extensively studied CAG-repeat, which 
Abstract 
Background In a previous population-based study on 
3369 European men with self-reported prostate cancer 
(PCa), it was shown that androgen receptor (AR) haplotype 
designated H2 was associated with high levels of serum 
PSA (prostate-specific antigen) concentration, and, at the 
same time, with low risk for PCa. The aim of this study 
was to replicate this finding in other cohorts, with registry-
based cancer diagnosis.
Methods Using data from two population-based cohorts; 
the Malmö Diet and Cancer Study (MDCS, n = 12,121) 
and the Swedish Osteoporotic fractures in men study 
(MrOS, n = 1,120), 628 men with PCa and 1,374 controls 
were identified and genotyped. PCa data were collected 
from the Swedish national cancer registry. PCa odds ratios 
(ORs) and 95% confidence intervals (CIs) were calculated 
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encodes for a varying number of the amino-acid glutamine, 
and the GGN repeat, encoding for a chain of glycines [2–4]. 
Apart from the repeats, the AR also holds a single-nucleo-
tide polymorphism (SNP) in its first exon (rs6152) located 
in between the CAG- and the GGN-repeats. This variant is 
a synonymous GAG > GAA substitution in codon E213 and 
is also sometimes referred to as StuI as the presence of the 
G-allele allows for digestion with the restriction enzyme 
Stu I [5].
We have recently, in the community-based European 
Male Ageing Study (EMAS), consisting of 3369 men, 
between 40 and 80 years of age and from eight European 
centers, identified two different AR haplotypes [6]. The 
16% of men with the minor haplotype (designated H2), 
to which the minor A-allele of E213 belongs, exhibited a 
nearly twofold increased risk of having serum PSA above 
3 and 4 ng/mL, which are clinically used cut-off values for 
further investigation on the suspicion of PCa. Yet, these 
men were only one-third as likely to be diagnosed with PCa 
after 4 years of follow-up compared to subjects carrying the 
G allele (H1). However, as the number of PCa cases was 
relatively small and PCa self-reported, the objective of cur-
rent work was to replicate the previous study regarding PCa 
risk in two other cohorts, with cancer cases collected from 
the Swedish National Cancer Registry.
Materials and methods
Study design
The study was based on two cohorts:
1. The Malmö Diet and Cancer Study (MDCS), from 
which a nested case–control population consisting of 
PCa cases and controls was extracted [7];
2. The Malmö and Gothenburg parts of the Swedish 
Osteoporotic fractures in men study (MrOS), which is 
a prospective study on osteoporosis in men [8].
Men with sufficient amount of DNA in the bio-bank had 
been genotyped regarding SNPs in the AR gene. These 
SNPs were designed to capture all variation in the gene.
Written informed consent was obtained from all partic-
ipants. The study was approved by the ethical committee 
board at Lund and Gothenburg Universities, respectively.
MDCS, nested case–control study
In the period 1991–1995, men born between 1923 and 1945 
(n = 31,514) and women (n = 42,624) born 1923–1950 and 
living in the city of Malmö, Sweden were invited to par-
ticipate in a prospective study on western diet and lifestyle 
factors in relation to cancer [9]. The only exclusion criteria 
were mental incapacity or insufficient Swedish language, 
leaving 68,905 eligible subjects of which 28,873 were men. 
Of these, 12,121 men accepted the invitation to participate 
in the MDCS study, 38% of the target male population 
(Fig. 1a).
Using the Swedish National Cancer Registry, 661 
prevalent cases of PCa in the MDCS cohort who were 
still alive as of 2006 were identified; 5% of the enrolled 
men. Each man with PCa was matched with a control 
based on age (±90 days) and date of enrollment (±90 
days) resulting in 1,322 eligible men. Of these, 975 men 
(74%) agreed to participate in a nested case–control 
Fig. 1  Flow charts describing 
the exclusion process in the 
cohorts a MDCS and b MrOS
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study, initiated for a study regarding PCa in relation to 
number of children [7]. Those who accepted the invita-
tion and those who did not respond to the invitation were 
of similar age, with the mean age and standard devia-
tion (SD) being 74.3 years (SD ± 5.7) and 75.4 years 
(SD ± 6.0), respectively. Of the participants, 25 were 
excluded due to insufficient DNA quantity in the bio-
bank, while genotyping failed in 13 cases. Five controls 
were discovered as misclassified and, therefore, trans-
ferred to the group of PCa cases, giving a total number 
of 458 cases and 425 controls that were genotyped. Of 
these, 421 (89%) and 389 (89%), respectively, reported 
that they were born in Sweden. The 68 men born outside 
of Sweden represented 20 countries, with most men born 
in Denmark (n = 10), Germany (n = 7), Hungary (n = 5), 
Yugoslavia (n = 4), and Norway (n = 3). The number of 
men who had not reported birth-country was 32.
The Swedish MrOS study
The Swedish part of the MrOS Study, originally initiated 
to study osteoporotic fractures in men, consisted of 3014 
men, aged 69 to 81 years (mean age at inclusion 75.4 
years) from three centers (Malmö, n = 1005; Uppsala, 
n = 999; and Gothenburg, n = 1010). These men were 
randomly identified using national population registries 
and enrolled between October 2001 and December 2004. 
To be eligible for the study, the participants had to be 
able to walk without aid and able to complete a ques-
tionnaire. There were no other exclusion criteria [8]. The 
inclusion rate at baseline for the Swedish part of MrOS 
was 45%. Only the subpopulations from Malmö and 
Gothenburg had been genotyped and, therefore, n = 2015 
men from the Swedish MrOS study were eligible for 
inclusion (Fig. 1b).
Since the prerequisite for both the previous study on 
European men using the EMAS cohort and the MDCS 
was that the men were alive at endpoint, only the men 
in the MrOS that were alive when the cancer data were 
accessed from the National Prostate Cancer Registry 
in December 2013 (mean time to registry search 10.4 
years) were included. Genotype data were available for 
1120 of these men (59%); mean age at registry search 
was 84.2 years (SD ± 2.9). Both prevalent and incident 
prostate cancers were included in the analyses (n = 171).
The genotyping of the MrOS subjects was based on 
blood sampling performed at the initiation of the study. 
By assessing the distribution of H1 and H2 haplotypes 
among the768 men who had died between the start of 
the MrOS study and the registry search in December 
2013, selection bias was estimated.
Genotyping
The HapMap database (Release 27) was used to select hap-
lotype-tagging SNPs (htSNPs) capturing all variation (with 
R2 > 0.80) within the gene and 20 kilobases upstream and 
downstream of it, using the Tagger Multimarker algorithm 
and restricting htSNPs to those with a minor allele fre-
quency (MAF) >5% in the HapMap CEU samples (http://
www.hapmap.org).
The nested MDCS samples genotyping was performed 
using the Sequenom iPLEX Gold assay and MassARRAY 
matrix-assisted laser desorption/ionization time-of-flight 
(MALDI-TOF) platform in accordance with the manufac-
turer’s instruction (Sequenom Inc., San Diego, CA, USA), 
whereas the MrOS samples were analyzed by matrix-
assisted laser desorption ionization–time-of-flight mass 
spectrometry on the Sequenom MassARRAY platform 
(San Diego, CA, USA). Assays were performed with ran-
domly sorted samples and controls.
Genotype information was collected from the Euro-
pean population (EUR) in the phase 1 data from the 1000 
genomes project (http://www.ensembl.org/). Genotype 
data on the SNPs used in EMAS and in MrOS/MDCS 
were pairwise calculated regarding linkage disequilibrium 
and for identification of SNPs with the highest haplotype 
predictability.
When the SNPs used in current study were com-
pared with the SNPs used in the previous EMAS cohort, 
rs6624304 had the highest haplotype predictability (r2 
range; 0.889–0.944), where the T-allele belonged to the 
PCa low-risk haplotype H2. In other words, in the Euro-
pean subpopulation of 1000 genomes, the allele of the hap-
lotype marker used in the EMAS (rs1204038) could be pre-
dicted by the allele in rs6624304 in 99% of the subjects. 
All the SNPs that in the EMAS cohort were found to be 
in high linkage disequilibrium, quantified as high r2 values, 
and were also in the EUR subpopulation of 1000 genomes 
found to have high r2.
Statistics
Logistic regression was used to calculate the odds ratio 
(OR) and 95% confidence interval (CI) for having PCa in 
relation to the rs6624304 genotype. All calculations were 
performed both with and without age adjustments. In the 
MDCS study, calculations were done for the whole cohort 
as well as for those born in Sweden only.
Only men alive in December 2013 were used in the cal-
culations on PCa risk in the MrOS cohort. For this cohort, 
in addition, the genotype-related OR for dying during the 
period between study initiation and December 2013 was 
calculated. Since cause of death was not available, to rule 
out that carriers of one haplotype had a more aggressive 
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PCa than the other one, the number of days between PCa 
diagnosis and death was investigated using linear regres-
sion. In addition, for the included cases, tumor data (Glea-
son, PSA, Metastasis, Nodes, Tumor stage) at the time of 
diagnosis for the two haplotypes were compared using 
Mann Whitney U test and Pearson’s Chi-square test.
Comparison of haplotype frequencies in the different 
cohorts to the European subpopulation from 1000 genomes 
was done using Fisher’s exact test. All calculations were 
performed in SPSS 22 Software (SPSS, Inc., Chicago, 
USA).
Results
Haplotype distribution compared to European 1,000 
genomes cohort
In the current study, as in the four subpopulations of 
1,000 genomes, the H1 haplotype was the most common 
haplotype in European populations. H1 is also the only 
haplotype present in East Asian populations, while H2 is 
the most common in the African populations (Table 1).
The allele frequencies in MDCS and MrOS did not dif-
fer from the European 1000 genomes subcohort (p = 0.406 
and p = 0.514, respectively).
Prostate cancer risk
The frequency of prevalent PCa was higher at inclusion in 
MrOS than in MDCS (9 vs 5%).
In the MDCS, the minor haplotype H2 was associated 
with 35% decreased odds for PCa, in all men as well as in 
those born in Sweden only (Table 2).
In the MrOS subjects, the same tendency, although 
without reaching the level of statistical significance, was 
observed.
In the merged cohort, the odds for being diagnosed with 
PCa were 32% lower in carriers of H2 as compared to those 
with H1.
Table 1  Frequency of each haplotype, represented by the allele frequencies in rs6624304, in the reported PCa cases and controls, as well as the 
1000 genomes subpopulations, n (%)
MDCS MrOS AMR AFR ASN EUR
H1; rs6624304C 747 (85) 951 (85) 218 (81) 32 (10) 428 (100) 495 (86)
H2; rs6624304T 136 (15) 169 (15) 51 (19) 283 (90) 0 (0) 79 (14)
Table 2  Frequency of 
rs6624304 in PCa cases and 
controls
Odds ratios for PCa calculated with the major allele as reference
*Significant at the 0.05 level
a Adjusted for age at inclusion in the current study (MDCS) or age at examination (MrOS)
b Marker for H1 and H2, and C- and T-allele, respectively
c Swedish
Study Cohort PCa, n (%) Controls, n (%) OR (95% CI) p OR (95% CI)a Pa
MDCS
 rs6624304b
  C 400 (87) 347 (82) Reference 0.020* Reference 0.021*
  T 58 (13) 78 (18) 0.65 (0.45–0.93) 0.65 (0.45–0.94)
MDCSc
 rs6624304b
  C 356 (87) 309 (82) Reference 0.022* Reference 0.023*
  T 51 (13) 70 (18) 0.63 (0.43–0.94) 0.64 (0.43–0.94)
MrOS
 rs6624304b
  C 150 (88) 801 (84) Reference 0.266 Reference 0.275
  T 21 (12) 148 (16) 0.76 (0.47–1.24) 0.75 (0.47–1.24)
Merged
 rs6624304b
  C 550 (87) 1148 (84) Reference 0.025* Reference 0.008*
  T 79 (13) 226 (16) 0.73 (0.55–0.96) 0.68 (0.51–0.90)
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Tumor characteristics at diagnosis did not differ between 
the carriers of the different haplotypes (Table 3).
Mortality risk in relation to haplotype
In the 768 deceased men, 660 (86%) and 108 (14%) were 
carriers of H1 and H2, respectively. There were no sig-
nificant differences in mortality between the groups, nei-
ther before nor after adjustment for age at inclusion, OR 
(95% CI) for H2: 0.90 (0.69–1.18), p = 0.444 and 0.92 
(0.71–1.20), p = 0.546, respectively. Of the deceased men 
with a PCa diagnosis, n = 168 had been genotyped for the 
AR variant. For these men, the number of days between 
diagnosis and all-cause death did not differ between the 
two haplotypes (mean (SD) H1: 2,871.01 (2,119.52), H2: 
3,008.32 (1,343.00), p = 0.742; adjusted for age at inclu-
sion: p = 0.765).
Discussion
The previous finding regarding an association between 
AR haplotype (H2) and low-risk for Europeans for being 
diagnosed with PCa was replicated in the current study. 
Although the same tendency was observed in both cohorts 
investigated, it was statistically significant in the larger 
MDCS, but not in the MrOS, most probably due to the cir-
cumstance that the MrOS subcohort was smaller and the 
statistical power, therefore, relatively low. Another expla-
nation could be selection bias, with a higher proportion of 
men with PCa assigning for participation in MrOS. It is 
well known that a cornerstone in treatment of PCa is andro-
gen ablation, and androgen deficiency, in turn, is a risk fac-
tor for osteoporosis. Of the men with PCa, up to 53% are 
affected by this bone disorder [10]. These men could, there-
fore, be more inclined to participate in a prospective study 
on osteoporosis when contacted than men without PCa. 
However, this circumstance would not affect the frequen-
cies of the genetic variants.
Our findings have interesting clinical and biological 
implications. We have previously reported that the H2 
Table 3  Comparison of tumor 
characteristics for the two 
alleles of rs6624304
rs6624304C, n (%) rs6624304T, n (%)
PSA (ng/µl)
 Unknown, n (% of cases) 244 (44) 24 (30)
 PSA median (25–75 percentile) 9.15 (5.60–16.00) 8.40 (5.90–17.10)
 PSA < 10, n (%) 162 (53) 34 (62)
 PSA 10-19.9, n (%) 82 (27) 12 (22)
 PSA > 20, n (%) 62 (20) 9 (16)
Gleason score
 Unknown, n (% of cases) 122 (22) 17 (22)
 Gleason median (25–75 percentile) 6 (6–7) 6 (6–7)
 Gleason < 7 247 (58) 34 (55)
 Gleason 7 134 (31) 18 (29)
 Gleason > 7 47 (11) 10 (16)
Tumor stage
 Unknown, n (% of cases) 63 (11) 8 (10)
 T0 4 (1) 0 (0)
 T1 225 (46) 29 (41)
 T2 170 (35) 28 (39)
 T3 82 (17) 14 (20)
 T4 6 (1) 0 (0)
Nodes
 Unknown, n (% of cases) 417 (76) 59 (75)
 N0 128 (96) 19 (95)
 N1 5 (4) 1 (5)
Metastasis
 Unknown, n (% of cases) 266 (48) 37 (47)
 M0 275 (97) 41 (98)
 M1 9 (3) 1 (2)
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carriers without PCa have a 65% higher odds of hav-
ing PSA levels above the level of 3 or 4  ng/mL, which 
generally are used as cut points for referral to urological 
examination, including prostate biopsies [6]. Although no 
PSA data were available for the participants without PCa 
in the cohorts included in this study as they were from 
the general population and not originally participating in 
a study on PCa, the combination of a lower risk of mani-
fest PCa in a group of men previously found to be more 
likely to present with high PSA due to a certain inherited 
gene variant calls for efforts to develop genotype adjusted 
normal ranges for this cancer marker. It is possible that 
inclusion of the SNP E213 could improve the perfor-
mance of the PSA-test.
When tumor characteristics were compared for the two 
haplotypes, no differences in aggression or stage were 
found. However, many cases were missing detailed tumor 
data. Tumor stage, the most complete variable (10% miss-
ing values), did not indicate any overrepresentation of men 
in any category.
In a previous study on PCa, on men from the Cancer 
Prostate in Sweden (CAPS) cohort, those with the A-allele 
of rs6152, part of our minor H2-haplotype, had a signifi-
cantly reduced risk of developing PCa [11]. However, when 
the study was replicated in seven pooled cohorts (5 Ameri-
can and 2 European), the variant was no longer associated 
with reduced PCa risk [12].
The haplotype reported by us as implying lower PCa risk 
appears to be the most common haplotype in African pop-
ulations, while the high-risk haplotype is the only haplo-
type in East Asia. This is contradictory to the incidence of 
PCa in these populations, as several studies have reported 
higher risk of PCa in African-American men in comparison 
with Caucasians and the incidence of PCa is much lower in 
Asian countries than elsewhere [13]. This indicates that the 
biological mechanisms linking this particular AR haplotype 
to the risk of PCa are highly dependent on other factors, 
of which some can be lifestyle-related, whereas others are 
likely to be genetic. This could also explain why the study 
by Lindström et  al. [12] failed to repeat the results in the 
larger data set consisting of a more genetically diverse pop-
ulation, where population stratification bias could dilute the 
effect of the genetic variants.
This contradictory relationship between haplotype 
distribution and population risk also seems to apply for 
androgenic alopecia. Studies regarding this condition 
have reported alleles included in the H1 haplotype to 
be associated with increased risk of male pattern bald-
ness [14–18]. In addition, for this condition, although 
the highest frequencies of risk alleles are found in Asian 
men, their risk of male baldness is 50% lower than 
among Europeans [15]. A meta-analysis comprising more 
than 2000 men from several countries found that the 
association between the E213 variant that belongs to the 
H2 haplotype and baldness was applicable for Caucasians 
only [18].
A limitation of our study was that only men who were 
alive at follow-up were included. Since age at endpoint 
was relatively high in both cohorts, information may have 
been lost due to exclusion of men with a shorter life-span 
or more aggressive early onset PCa. However, in the cur-
rent study, there was no significant difference in all-cause 
mortality between the men with the two haplotypes dur-
ing the 10-year follow-up period and no difference in the 
number of days between diagnosis and all-cause death 
in the deceased men with PCa. Furthermore, finding of 
similar distribution of the two haplotypes in the current 
study as in Europeans in the 1000 genomes study speaks 
against significant selection bias.
Another point of criticism could be the use of differ-
ent SNPs as markers of the H1/H2 haplotype in EMAS 
(rs1204038) and in the current study (rs6624304). How-
ever, we do not consider this as a significant problem as 
the former SNP can be predicted by the allele in the latter 
in 99% of the cases in European cohorts.
The strength of the study was access to the Swedish 
National Cancer Registry, which is a mandatory regis-
try of all cancers in Sweden with an approximated com-
pleteness of registration of 99%, ensuring a complete 
assessment of PCa diagnosis. Moreover, the current 
study included approximately ten times as many PCa 
cases compared to our previous study on European men 
(EMAS), and, also, in the current study, men with the H2 
haplotype had one-third lower odds of being diagnosed 
with PCa compared to counterparts with the most com-
mon haplotype H1.
In summary, based on two large Swedish community-
based populations, we have confirmed the previous indi-
cation that 15% of European men who are carriers of the 
second most frequent AR haplotype have approximately 
one-third lower odds of PCa than counterparts with the 
most frequent AR variant.
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